上海睿智药代药动与早期毒理部门由生物分析（GLP和Non-GLP），体外药代动力学（in vitro ADME），体内药代动力学（PK）以及早期毒理（non-GLP Toxicology）四部分组成。部门的管理团队由曾就业于国际各知名药企的科学家担任，注重药代学/毒理学实验的科学性以及结果的严谨性，同时强调把药代学/毒理学实验的结果整合到具体的药物研发项目当中去。部门多年来也一直承接着诸多药企和初创公司委托的新药申报项目。
Since 2007, extensive ADME profiling (80,000+) and PK and exploratory toxicology studies (50,000+) have been conducted to support numerous drug discovery and development programs with our worldwide partners. Working closely with ChemPartner’s internal biology/pharmacology, and antibody engineering teams, our DMPK group supports translational medicine through our expertise in formulation development, in vitro-in vivo extrapolation, PK/PD modeling, biomarker analysis, and metabolomics.
我们视客户的成功为成功并以客户的成功而骄傲。
